A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities

Acta Pharmacologica Sinica

Volumn 33, Issue 2, 2012, Pages 148-154

  Min, He ^a   Ni, Guan ^a   Gao, Wei Wei ^a   Qing, Liu ^a   Wu, Xiao Yan ^a   Ma, Da Wei ^b   Zhong, Da Fang ^a   Ge, Guang Bo ^c   Chuan, Li ^a   Chen, Xiao Yan ^a   Ling, Yang ^c   Liao, Jia Yu ^a,d   Wang, Ming Wei ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

^c DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^d University of California Riverside   (United States)

Author keywords

Boc5; G protein coupled receptor; glucagon like peptide 1; non peptidic agonist; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BOC 5; CYCLOBUTANE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INSULIN; UNCLASSIFIED DRUG; WB 4 24;

ANTIDIABETIC ACTIVITY; BODY FAT; BODY WEIGHT; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; ENERGY METABOLISM; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SATIETY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ANIMALS; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; RECEPTORS, GLUCAGON;

EID: 84863141835     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.169     Document Type: Review

References (36)

1. Report of the expert committee on the diagnosis and classifcation of diabetes mellitus. Diabetes Care 2003; 26 Suppl 1: S5-20.
2. Screening for Type 2 Diabetes. Report of a World Health Organization and International Diabetes Federation meeting. 2003. Available from: http://www.who.int/diabetes/publications/en/screening-mnc03.pdf
3. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005; 4: 361-70. (Pubitemid 41751172)
4. Meier JJ, Nauck MA. The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 2004; 5: 402-10.
5. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastro-entero logy 2007; 132: 2131-57. (Pubitemid 46711096)
6. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-7. (Pubitemid 32222398)
7. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609-24.
8. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefts beyond glycaemic control? Br J Clin Pharmacol 2009; 57: 1340-51.
9. Eglen RM. GPCRs revisited: new insights lead to novel drugs. Pharmaceuticals 2011; 4: 244-72.
10. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A 2007; 104: 937-42. (Pubitemid 46154715)
11. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with effcacy in diabetic db/db mice. Proc Natl Acad Sci U S A 2007; 104: 943-8. (Pubitemid 46154716)
12. Gong YD. A novel 3-(8-Chloro-6-(trifluoromethyl)imidazo[1,2-a] pyridine-2-yl)phenyl acetate skeleton and pharmacophore model as glucagon-like peptide 1 receptor agonists. Bull Korean Chem Soc 2010; 31: 3760-4.
13. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 2010; 59: 3099-107.
14. Wang MW, Liu Q, Zhou CH. Non-peptidic glucagon-like peptide-1 receptor agonists: aftermath of a serendipitous discovery. Acta Pharmacol Sin 2010; 31: 1026-30.
15. Liao JY, Hong YF, Wang Y, Von geldern TW, Zhang KE. Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators. WO Patent 2011094890. 2011; August 11.
16. Su H, He M, Li H, Liu Q, Wang J, Wang Y, et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS ONE 2008; 3: e2892.
17. He M, Su H, Gao W, Johansson SM, Liu Q, Wu X, et al. Reversal of obesity and insulin resistance by a non-peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLoS ONE 2010; 5: e14205.
18. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011; 152: 3103-12.
19. Liu Q, Li N, Yuan YY, Lu HL, Wu XY, Zhou CH, et al. Cyclobutane derivatives as novel non-peptidic small molecule agonists of glucagon-like peptide-1 receptor. J Med Chem 2011. Doi: 10.1021/jm201150j.
20. Parnell JA. Differential secretion of satiety hormones with progression of obesity in JCR:LA-corpulent rats. Obesity 2008; 16: 736-42. (Pubitemid 351465626)
21. Toft-Nielson M, Madsbad S, Holst JJ. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 1996; 45: 552-6. (Pubitemid 26140536)
22. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35. (Pubitemid 39441462)
23. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100. (Pubitemid 40616618)
24. Fineman M. Antibodies to exenatide did not cross-react with human GLP-1 or glucagon or alter the efficacy or safety of exenatide. Diabetologia 2010; 53: S342.
25. Buse JB. The incidence of antibody formation and the levels of antibodies are lower with liraglutide than exenatide in a head-to-head comparison. Diabetologia 2010; 53: S341.
26. Hermanson GT. Preparation of hapten-carrier immunogen conjugates. In: Hermanson GT, editor. Bioconjugate Techniques. New York: Academic Press; 2008. p 745-82.
27. Singh KV, Kaur J, Varshney GC, Raje M, Suri CR. Synthesis and characterization of hapten-protein conjugates for antibody production against small molecules. Bioconjugate Chem 2004; 15: 168-73. (Pubitemid 38165992)
28. Hutchings CL, Gilbert SC, Hill AV, Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 2005; 175: 599-606. (Pubitemid 40884366)
29. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91. (Pubitemid 40616617)
30. Zinman B, Hoogwerf BJ, Duran Garcia S, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-85. (Pubitemid 351650556)
31. Reidelberger RD, Haver AC, Apenteng BA, Anders KL, Steenson SM. Effects of exendin-4 alone and with peptide YY(3-36) on food intake and body weight in diet-induced obese rats. Obesity 2011; 19: 121-7.
32. Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK. The effect of exenatide re-exposure on safety and efficacy. Peptides 2009; 30: 1771-4.
33. Stenkamp RE, Teller DC, Palczewski K. Crystal structure of rhodopsin: a G-protein-coupled receptor. ChemBioChem 2002; 3: 963-7. (Pubitemid 35177747)
34. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-65. (Pubitemid 350172884)
35. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 2010; 285: 723-30.
36. Dezelak M, Bavec A. Third intracellular loop of glucagon like-peptide-1 receptor is coupled with endogenous mono-ADP-ribosyltransferase - novel type of receptor regulation? Eur J Pharmacol 2011; 666: 35-42.